Acute Ischemic Stroke
Conditions
Keywords
Acute Ischemic Stroke, AIS, Ischemic Stroke, Stroke
Brief summary
This is a trial to evaluate the safety and effect of three intravenous (IV) doses of NTS-521 for the early recovery treatment of acute ischemic stroke (AIS). Participants will be followed for 90 days.
Detailed description
Stroke represents a major global public health crisis, characterized by a paradox: declining age-standardized rates yet a rapidly expanding absolute global burden. According to recent epidemiological analyses from the Global Burden of Disease (GBD) study there were 11.9 million incident strokes worldwide in 2021, corresponding to a global age-standardized incidence rate of 141.5 per 100,000 person-years. Stroke claimed 7.3 million lives (an age-standardized mortality rate of 87.4 per 100,000), making it the third leading cause of mortality worldwide, accounting for 10.7% of all deaths. The trial's target population for NTS-521 intervention consists of participants undergoing endovascular thrombectomy (EVT), and/or intravenous thrombolysis (IVT), or medical care without reperfusion treatment.
Interventions
DRUGNTS-521
Intravenous NTS-521
OTHERPlacebo Control
0.9% saline solution delivered intravenously
Sponsors
NeuroTrauma Sciences, LLC
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
Sponsor, Clinical Monitors
Intervention model description
This is a multicenter, randomized, double-blind, placebo-controlled parallel-arm trial to evaluate the safety and effect of three IV doses of NTS-521 vs placebo for the early recovery treatment of Acute Ischemic Stroke (AIS).
Eligibility
Sex/Gender
ALL
Age
45 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Acute ischemic stroke with moderate to severe hemiparesis * Functional independence in activities of daily living without requiring nursing care before the index stroke. * Consent process by participant or proxy, with reconsent provision. * Age ≥ 45 to ≤ 80 years of age (inclusive) on the date of randomization * Sufficient attention, comprehension, and cooperation to carry out instructions
Exclusion criteria
* Pre-existing motor deficit prior to index stroke * Posterior circulation ischemic stroke * Lacunar stroke * Qualifying brain imaging demonstrating intracranial hemorrhage, malignant middle cerebral artery (MCA) infarct with edema, or bilateral/multifocal infarcts, clinically significant vascular malformation, brain tumor, or other central nervous system (CNS) pathology * Recent major surgery or trauma (\<30 days)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety Assessment | Safety assessments between baseline and Day 30 and Day 90 | Count of incident adverse events by treatment arm, including Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Suspected Unexpected Serious Adverse Reaction (SUSARs) as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI - CTCAE v6.0), Vital signs and electrocardiograph (ECG) assessed by descriptive statistics, shift tables, and normal range criteria, and standard biochemical and hematology laboratory panel, assessed by descriptive statistics, shift tables, and normal range criteria |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Fugl-Meyer- Upper Extremity Motor Score (FMA-UE) | Change from Baseline Total Fugl-Meyer-Upper Extremity Motor Score, assessed as a continuous variable to Day 90 | Change from baseline to Day 90 in the FMA-UE motor score (0-66; higher is better) |
| National Institutes of Health Stroke Scale Assessment (NIHSS) | Assessed as a continuous variable from baseline to Day 90 | National Institutes of Health Stroke Scale (0-42; higher is worse) |
| Modified Rankin Score (mRS) | Assessed as an ordinal variable from Baseline to Day 90 | Modified Rankin Score (mRS) (0-6; higher is worse), assessed as an ordinal variable |
| EuroQual-5D-5L Assessment (EQ-5D-5L) | Assessed as a continual variable from Baseline to Day 90 | Change from baseline to Day 90 for EQ-5D-5L Quality of Life Assessment Score (5 to 25, lower indicating better quality of life) |
Contacts
CONTACTScott C Oshana, BS
CONTACTAllison Ward, MSA, MSEd
PRINCIPAL_INVESTIGATORBijoy A Menon, MD
The University of Calgary Stroke Program & Stroke Clinical Trial Group
Outcome results
None listed